Coexisting inflammatory bowel disease and eosinophilic esophagitis: moving beyond parallel narratives to an integrated framework.

INTRODUCTION

Eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) are chronic immune-mediated gastrointestinal disorders traditionally framed as biologically distinct, yet epidemiologic data increasingly support a bidirectional association.

AREAS COVERED: This narrative review examines the epidemiology,immunopathogenesis, and clinical implications of coexisting EoE and IBD using a targeted PubMed search through 2025 with reference-list screening. Although EoE is classically driven by type 2 inflammation and IBD by Th1/Th17 pathways, both disorders converge on epithelial barrier injury, innate immune dysregulation, and fibroblast-mediated remodeling. These shared downstream mechanisms may help explain diagnostic overshadowing, treatment resistance, and an increased propensity for fibrostenotic complications in patients with dual disease.

EXPERT OPINION: Coexisting EoE and IBD may be better viewed less as a chance overlap and more as a potentially meaningful clinical association. A mechanism-based approach that incorporates risk enrichment, early endoscopic evaluation, nutritional comanagement, and therapies directed at shared inflammatory-fibrotic pathways may improve outcomes. Future progress will depend on prospective cohorts, biomarker development, and trials that intentionally include patients with both conditions.